New England Journal of Medicine· 2020Q1
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
- 2,171citations
- Q1SCImago
- 2020year
Short summary
This study found no evidence that continuing renin–angiotensin–aldosterone system (RAAS) inhibitors increases the risk of severe Covid-19 outcomes or mortality.
AI-generated from the title and abstract; the full text is not read.
Key points
- Continuing RAAS inhibitors does not increase the risk of severe Covid-19.
- Continuing RAAS inhibitors does not increase mortality in Covid-19 patients.
- The study provides evidence to guide treatment decisions for patients on RAAS inhibitors during the pandemic.
AI-generated from the title and abstract; the full text is not read.
Abstract
RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain. The authors hy...
The authors' abstract, as published at the source. New England Journal of Medicine, 2020 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine